Journal Article DZNE-2026-00225

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2026
Elsevier [Amsterdam u.a.]

NeuroImage: Clinical 49, 103963 () [10.1016/j.nicl.2026.103963]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Recent studies demonstrated strong agreement between early-phase β-amyloid-PET perfusion imaging and glucose hypometabolism assessed by [18F]FDG-PET, indicating the potential of early-phase β-amyloid-PET as a surrogate biomarker of neuronal injury. We therefore aimed to investigate the additive value of early-phase β-amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia syndromes in clinical routine.[18F]florbetaben- and [18F]flutemetamol-PET scans (n = 379) performed between July 2013 and July 2021 were analyzed for their amyloid status and the presence of a neurodegenerative hypoperfusion pattern using visual assessment and z-score maps. In patients visually rated as amyloid-negative/neurodegeneration-positive (A-N+), the most likely diagnosis based on perfusion patterns was compared to the final clinical diagnosis, i.e. frontotemporal dementia or psychiatric disorders, suspected 4R-tauopathy, and suspected non-Alzheimer pathophysiology. Logistic regression models based on a data-driven selection of cerebral regions of hypoperfusion by principal component analysis were used to predict neurodegenerative disease and clinical diagnoses. Diagnostic accuracy was compared between visual assessment and the regression models.Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. Visual assessment assigned 75.3% (67/89) of A-N+ patients to the correct diagnostic category. In contrast, the regression model classified 69.7% (62/89) of patients.The current study demonstrates an additive value of early-phase β-amyloid-PET for the differential diagnosis of dementia syndromes. While visual assessment of early-phase β-amyloid-PET already provides substantial diagnostic accuracy, a data-driven analysis approach could aid in cases of uncertainty.

Keyword(s): 4-repeattauopathy ; Data driven ; Early-phaseβ-amyloid-PET ; Frontotemporal dementia ; Multinomial logistic regression ; Suspected non-Alzheimer pathophysiology

Classification:

Contributing Institute(s):
  1. Clinical Research (Munich) (Clinical Research (Munich))
  2. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)
  3. Clinical Neurodegeneration (AG Levin)
  4. Molecular Neurodegeneration (AG Haass)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
  2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Database coverage:
Medline ; DOAJ ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > M DZNE > M DZNE-Clinical Research (Munich)
Document types > Articles > Journal Article
Institute Collections > M DZNE > M DZNE-AG Dichgans
Institute Collections > M DZNE > M DZNE-AG Haass
Institute Collections > M DZNE > M DZNE-AG Levin
Documents in Process
Public records
In process

 Record created 2026-02-26, last modified 2026-02-26


Restricted:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)